NasdaqGM - Nasdaq Real Time Price USD

Ikena Oncology, Inc. (IKNA)

1.2600

+0.0200

(+1.61%)

At close: April 18 at 4:00 PM EDT

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. Details are as follows: Date: Tuesday, April 16, 2024Time: 2:00 p.m. ETWebcast

GlobeNewswire 8 days ago
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”)

GlobeNewswire last month
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA. The Company will also be holding one-on-one investor meetings at the conference. Details on the panel can be found below: Ikena Panelist:

GlobeNewswire last month
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595 Sergio Santillana, M.D., MSc., MBA resigned from current role as Chief Medical Officer BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new

GlobeNewswire last month
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources from exploratory discovery to clinical development of IK-930 and IK-595 Ended 2023 in strong financial position with approximately $175 million in cash; runway extended into 2H 2026 BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire 2 months ago
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging signs of clinical activity and tumor shrinkage in multiple patients with difficult-to-treat epithelioid hemangioendothelioma (EHE) during dose escalation Additional IK-930 clinical data update planned for the second half of 2024; increased focus on enrollment of targeted populations i

GlobeNewswire 5 months ago
Ikena Oncology to Present at Multiple November 2023 Investor Conferences

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November. Details are as follows: Stifel Healthcare Conference, November 14-15, 2023One-on-One Investor Meetings November 14, 2023Presentation: November 14, 2023 at 1:50pm EST Jefferies London Healthcare Conference, Novemb

GlobeNewswire 5 months ago
Ikena Oncology to Participate in September 2023 Investor Conferences

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Details are as follows: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023One-on-One Investor Meetings September 11, 2023Fireside Chat: Monday, September 11, 2023, at 3:35pm ETWebca

GlobeNewswire 7 months ago
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by year end 2023 Underwritten public offering and acquisition of Pionyr add over $80M to balance sheet BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announce

GlobeNewswire 8 months ago
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing o

GlobeNewswire 8 months ago
Ikena Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in TD Cowen’s 4th Annual Oncology Innovation Summit taking place May 30-31, 2023, and the Jefferies Healthcare Conference taking place June 7-9, 2023. Details are as follows: TD Cowen’s 4th Annual Oncology Innovation SummitFireside Chat: Wednesday, May 31, 2023 at 9:00 a.m. –

GlobeNewswire 10 months ago
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting demonstrated IK-930 TEAD1 selectivity with equivalent activity to panTEAD inhibition and significantly improved therapeutic index Differentiated MEK-RAF complex inhibitor profile of IK-595 presented at AACR Special Conference on Targeting RAS Underwritten offering of $40M extends runway into 2026 BOSTON, Ma

GlobeNewswire 10 months ago
Ikena Oncology Announces $40 Million Underwritten Offering

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $40 m

GlobeNewswire 10 months ago
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the Stifel 2023 Virtual Targeted Oncology Days, taking place April 25-26, 2023. Ikena’s Chief Executive Officer, Mark Manfredi, Ph.D., will present a corporate overview on Tuesday, April 25 highlighting adv

GlobeNewswire 11 months ago

Performance Overview

Return	IKNA	S&P 500
YTD	-36.04%	+5.06%
1-Year	-74.80%	+20.71%
3-Year	-93.00%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ikena Oncology, Inc. (IKNA)

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Ikena Oncology to Participate in September 2023 Investor Conferences

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena Oncology to Participate in Upcoming Investor Conferences

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Ikena Oncology Announces $40 Million Underwritten Offering

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Performance Overview